176 results about "Ovarian function" patented technology

The invention discloses a traditional Chinese medicine composition, a preparation method thereof and an application of the traditional Chinese medicine composition in preparation of a medicine for preventing and treating ovarian reserve hypofunction, and belongs to the technical field of traditional Chinese medicines. The composition is prepared from the following raw materials in parts by weight: 10 to 15 parts of radix paeoniae alba, 6 to 10 parts of radix bupleuri, 10 to 15 parts of radix rehmanniae preparata, 15 to 30 parts of stir-fried rhizoma dioscoreae, 12 to 20 parts of semen cuscutae, 10 to 12 parts of radix angelicae sinensis, 10 to 15 parts of poria cocos, 12 to 25 parts of fructus ligustri lucidi, 10 to 15 parts of radix salviae miltiorrhizae, 10 to 15 parts of fructus corni and 10 to 15 parts of radix morindae officinalis. The traditional Chinese medicine composition can obviously reduce the level of follicle-stimulating hormone (FSH) of cis-platinum model mice, increase estradiol (E2), increase the number of follicles at all levels, especially the number of primordial follicles, and reduce the number of atresia follicles; the ovarian function of naturally aged mice can be improved, FSH (follicle stimulating hormone) is reduced, anti-mullerian hormone (AMH) and E2 are increased, and the quantity of follicles at all levels, especially the quantity of corpus luteum, primordial follicles and anterior sinus follicles, is increased; therefore, the composition disclosed by the invention has an obvious protection effect on the hypoovarian reserve function.

The invention belongs to the technical field of cytotoxicity intervention, and particularly relates to application of an inhibitor JSH-23 in preparation of a medicine for preventing and / or treating ovarian toxicity caused by environmental toxin combined exposure. Aiming at the condition that MC-LR and NaNON combined exposure can activate NF-kappa B to induce KK-1 cell nitrification stress and cause mouse ovarian dysfunction, JSH-23 is selected as an intervention agent, and it is found that after KK-1 cells are pretreated by JSH-23, NF-kappa B nuclear translocation induced by the KK-1 cells due to MC-LR and NaNON combined exposure is remarkably inhibited, iNOS protein rising induced by toxin combined exposure is remarkably reduced, and NF-kappa B nuclear translocation induced by the KK-1 cells due to NF-kappa B combined exposure is remarkably inhibited. The increase of the levels of ONOO and 3-NT of nitration stress markers is effectively relieved, which indicates that JSH-23 can participate in the nitration stress of KK-1 cells caused by combined exposure of MC-LR and NaNO2 by inhibiting NF-kappa B activation, and a foundation is laid for screening antidotes after exposure of environmental toxins.

The invention provides a traditional Chinese medicine composition for treating ovarian reserve function decline. The traditional Chinese medicine composition is prepared from the following medicines in parts by mass: 9-30 parts of radix astragali preparata, 6-20 parts of roasted rhizoma atractylodis macrocephalae, 10-15 parts of poria cocos, 2-10 parts of radix glycyrrhizae preparata, 6-20 parts of semen cuscutae, 9-20 parts of radix dipsaci (dipsacus root), 6-12 parts of herba lycopi and 6-15 parts of lily. Experimental results show that the traditional Chinese medicine composition is suitable for improving the ovarian function of a patient suffering from spleen-kidney deficiency type ovarian reserve function decline.

The invention discloses application of an ACSL4 inhibitor in preparation of a medicine for improving quality reduction of an elderly ovum, and belongs to the technical field of biological medicines. The invention provides an application of targeting long-chain fatty acid acyl-coenzyme A synthetase 4 (ACSL4) in intervention of low oocyte quality and related fertility decline caused by aging. The ACSL4 inhibitor can be used for preparing drugs for improving ovarian functions and improving oocyte quality. In-vivo and in-vitro experiments prove that by inhibiting the ACSL4, the aging process of the elderly ovary can be effectively relieved, the expression of aging-related proteins p16 and p21 can be reduced, the mitochondrial function of the oocyte can be improved, and spindle assembly abnormality and chromosome arrangement defects can be rescued, so that the maturation rate and the development potential of the oocyte can be remarkably improved.

The invention provides application of a traditional Chinese medicine composition in preparation of a medicine for preventing and / or treating ovarian dysfunction, and belongs to the technical field of biological medicine. The traditional Chinese medicine composition comprises the following traditional Chinese medicine raw materials in parts by weight: 8-10 parts of American ginseng, 2-4 parts of pseudo-ginseng, 55-65 parts of kudzuvine root, 42-48 parts of coptis chinensis, 42-48 parts of scutellaria baicalensis, 14-16 parts of stiff silkworm, 14-16 parts of rhizoma zingiberis, 42-48 parts of bitter gourd and 55-65 parts of rhizoma anemarrhenae. The traditional Chinese medicine composition has the effects of increasing the number of follicles and corpus luteum, restoring the duration of an estrus cycle and restoring the levels of serum hormones and sex hormone receptors. The traditional Chinese medicine composition provided by the invention provides a new means for preventing and treating ovarian dysfunction.

The invention belongs to the field of animal model construction, and particularly relates to application of an NFATC2IP gene knockout mouse model. Experiments prove that after the NFATC2IP gene is knocked out, the mouse has the characteristic changes of ovarian weight reduction, volume reduction, estrus cycle disorder, fertility reduction, AMH reduction, FSH increase and the like. It is indicated that the NFATC2IP gene is a key factor for maintaining ovarian reserve and endocrine balance, and an NFATC2IP gene knockout mouse can be used for revealing the occurrence mechanism of ovarian dysfunction and can also be used for screening of novel ovarian protection drugs, research of a hormone regulation mechanism and discovery and verification of biomarkers.

The application discloses application of NCOA7 circular RNA nanoliposome in preparation of a drug for treating premature ovarian failure or ovarian reserve function decline, and belongs to the technical field of biological medicine.The present application proves that nuclear receptor coactivator 7 (NCOA7) can relieve ovarian aging and significantly improve the ovarian function and fertility of DOR patients.The present application finds that NCOA7 circular RNA nanoliposome treatment can significantly improve the NCOA7 protein expression level of DOR female ovarian granulosa cells, improve the aging phenotype and growth rate of the DOR female ovarian granulosa cells, and has no significant influence on the biological characteristics of the ovarian granulosa cells, thereby providing a new scheme for rescuing the ovarian function and improving the fertility of DOR women.

The invention provides a novel application of a raspberry extract. It is found through tests that any one of isoquercitrin, ellagic acid, vanillic acid, oleanolic acid, kaempferol-3-O-rutinoside, kaempferol-3-O-sophoroside, tiliroside, tormentic acid and raspberry extract can remarkably improve the activity of the human ovarian granular cells or remarkably improve the oxidative stress level, and the activity of the human ovarian granular cells can be remarkably improved. According to the present invention, the ovarian function can be effectively protected by the eight components, the ovarian function can be effectively protected by the eight components, or the mitochondrial membrane potential level can be significantly regulated and controlled, or the estrogen level in the microenvironment can be effectively maintained, such that the ovarian function can be effectively protected by the eight components, and the raspberry extract containing the eight components. The invention provides a new choice for ovarian function protection products, and also provides a new application for the substances.

The invention discloses application of paeonol in preparation of a product for improving liver functions and ovarian functions of laying hens in the later egg laying period, belongs to the technical field of feed additives, and particularly relates to application of paeonol in preparation of a product for improving liver functions and ovarian functions of laying hens in the later egg laying period. It is found that paeonol can significantly reduce the activity of glutamic-pyruvic transaminase in the liver, significantly reduce the content of cholesterol and the content of triglyceride in serum, significantly reduce hepatic cell fatty degeneration and lipid droplet aggregation in a hepatic tissue pathological section, relieve liver injury and lipid metabolism disorder, and significantly improve the liver function. The paeonol can effectively improve the fatty liver hemorrhagic syndrome of the laying hens in the later egg laying period, and the paeonol can recover the storage capacity of ovary by improving the survival rate of follicles, improve the egg laying performance of the laying hens and improve the egg laying rate.

The present application relates to the field of biological medicine and modernization of traditional Chinese medicine, and particularly relates to a therapeutic target, an inhibitor and a traditional Chinese medicine composition for treating ovarian hypofunction caused by oxidative stress and application thereof. The present application first determines SRC tyrosine kinase as a key drug target for preventing and treating the disease. The application of the SRC tyrosine kinase inhibitor (such as secaitinib) in preparing related drugs is provided, which can alleviate the damage of ovarian granulosa cells by inhibiting the SRC activity, down-regulating the expression of antioxidant enzyme related genes and reducing the level of active oxygen. Meanwhile, the present application provides a traditional Chinese medicine composition composed of mulberry, kudzu root, tuckahoe and medlar. The composition can improve the hormone level, enhance the antioxidant capacity, improve the ovarian function and fertility by inhibiting the SRC tyrosine kinase activity and the SRC-RAF1-MEK-ERK signal pathway. The present application provides a new solution for the targeted treatment of ovarian hypofunction and the modernization of traditional Chinese medicine.

The invention relates to application of a gene inhibitor in preparation of a medicine for treating ovulation dysfunction, and belongs to the field of biomedicine.The FST content in serum of a healthy person and an OD patient is compared, it is found that the FST content in serum of the OD patient is far higher than that in serum of the healthy person, and then it is obtained that the FST content can be used as the basis for judging that the patient suffers from ovulation dysfunction. Therefore, early intervention and treatment can be carried out on patients. According to the invention, the FST high-expression monkey model is successfully constructed, and the pathogenic effect of FST high expression on the OD pathogenesis process is obtained through research of the FST high-expression monkey model; the invention further designs specific shRNA (short hairpin ribonucleic acid) to successfully inhibit the expression of FST, and after the expression of FST is inhibited, the ovarian structure of the test monkey tends to be healthy, the follicular development is normal, and the ovulation regularity is recovered, and the results show that the inhibition of the FST gene has a remarkable promotion effect on the ovarian function.

The invention discloses application of spermidine in preparation of a preparation for improving fertility of female mammals, and belongs to the technical field of reproductive biology. According to the invention, spermidine with different concentrations is introduced into mice, and the effect of spermidine on ovarian hormone secretion, ovarian reserve level and follicle number of female mammals is determined in a diet intake manner, so that the fertility of female animals is improved; it is found that spermidine can effectively improve the ovarian function, increase the secretion level of E2, P4, LH and AMH hormones closely related to the ovarian function, reduce the number of atresia follicles of the ovarian and increase the litter birth number of female mice by 1-2, and the spermidine has good animal breeding and livestock raising application prospects.

The invention discloses an application of a small molecular compound and an analogue thereof in treating ovarian aging diseases. It is found for the first time that the exogenous supplementary adenosine or the analogues thereof can effectively recover or improve the ovarian function and can prevent and inhibit ovarian fibrosis, and therefore the exogenous supplementary adenosine or the analogues thereof can be used as potential drugs for recovering the female fertility.

The application discloses a doxorubicin scavenger for protecting ovarian fertility and a preparation method thereof, comprising a DNA complex wrapped by a red blood cell membrane, wherein the red blood cell membrane is surface-modified by an anti-Mullerian duct antibody alphaAMH; the doxorubicin scavenger is specifically combined with AMH which is highly expressed in ovarian tissues through alphaAMH, is enriched in the ovarian part in a targeted manner, adsorbs doxorubicin through a DNA fragment in the DNA complex, reduces toxic damage of doxorubicin to ovarian cells, and further protects ovarian fertility. The doxorubicin scavenger can adsorb injected doxorubicin Dox, reduce side effects of doxorubicin Dox on ovarian granulosa cells, and further protect ovarian function and fertility.

The invention discloses a synergistic anti-oxidation urolithin A composition and application thereof in improving the ovarian function direction, and relates to the technical field of biological medicine, and the active ingredients of the composition comprise 10-100 parts of urolithin A and 6-40 parts of coenzyme Q10. According to the composition disclosed by the invention, the used raw materials are food-grade raw materials such as urolithin A and coenzyme Q10, and the urolithin A and the coenzyme Q10 are matched within a certain range, so that a good synergistic interaction effect can be achieved, and the composition has a good antioxidant effect; meanwhile, the composition also has the effects of effectively improving the ovarian reserve function, regulating the hormone level, improving menstruation, skin, emotion, sleep and the like at a low dosage level, and is effective and safe.

The invention relates to an effect of an REV-ERBalpha agonist SR9009 in the aspect of delaying ovarian senescence, and aims at the problem of fertility decline caused by cliff-type decline of ovarian functions of women over 35 years old, the SR9009 is applied to activate an REV-ERBalpha circadian rhythm signal channel in ovarian tissues, inhibit excessive autophagy of granular cells and maintain a primordial follicle dormancy state, so that the agonist SR9009 can be used for delaying ovarian senescence. Therefore, the original follicle depletion speed is delayed, follicle storage is maintained, and the ovary reproductive function cycle is prolonged. The effect is verified by a mammal model: REV-ERBalpha protein expression in an ovary of an aging individual is reduced, rhythmicity expression is disordered, autophagy of granulosa cells can be effectively inhibited in the ovary of the aging individual intervened by the SR9009, and the number of residual primordial follicles and the number of total follicles are obviously greater than those of an untreated control group. The invention provides an innovative treatment strategy of targeted rhythm regulation and control for clinical intervention of ovarian aging.

The invention belongs to the technical field of medicines, and particularly relates to a pharmaceutical composition for improving ovarian function damage and degeneration and a preparation method thereof. The invention discloses the GnRH agonist effect of dihydromyricetin DMY for the first time, and the affinity of dihydromyricetin DMY to a GnRH receptor and the GnRH agonist effect of dihydromyricetin DMY are verified through in-vitro experiments. Model animal experiments further prove that the dihydromyricetin DMY has a protective effect on ovarian function impairment caused by chemotherapy. Experiments prove that the dihydromyricetin DMY is given while the cyclophosphamide (CTX) is used for chemotherapy, so that the damage of the dihydromyricetin DMY to the ovarian function during chemotherapy can be reduced, and a protection effect is also achieved on the recovery of the ovarian function after drug withdrawal. The protection effect is reflected on the endocrine function and the reserve function of the ovary, and the preserved ovary reserve function can achieve the pregnancy result after chemotherapy is finished, which indicates that the dihydromyricetin DMY also plays the protection effect on the fertility function of the ovary.

One aspect of the invention provides a method of ovarian protection by administering to a female subject a composition comprising Mullerian inhibiting substance (MIS). Ovarian protection can be an induced arrest of folliculogenesis to preserve fertility. In some embodiments, ovarian protection is oncoprotection, the protection of the ovarian function during a cytotoxic treatment, e.g., chemotherapy. Another aspect of the invention relates to a method of treating PCOS, the method comprising administering to a female subject a composition comprising recombinant MIS protein.

The present invention relates to the technical field of medical detection. Disclosed is a use of an ERAP2 detection reagent in the preparation of a product for predicting the prognosis of POI. Also disclosed in the present invention is a use of ERAP2 as a biomarker in the preparation of a product for predicting the prognosis of POI. The prognosis of POI is intermittent recovery of ovarian function and / or a pregnancy outcome. In the present invention, it has been found by means of experimental studies that a serum ERAP2 level has a significant association with the prognosis of a POI patient, is an independent influencing factor, and has relatively high specificity and sensitivity. Therefore, ERAP2 can serve as a biomarker for predicting the prognosis of POI. The present invention provides a theoretical basis and clinical practice guidance for the prognosis of POI, and has important application value.

Provided are a biological material for restoring ovarian functions, a preparation method therefor and the use thereof, relating to the technical field of biological materials. A large number of experiments verify that: it is found that a specific biological protein component for reversing ovarian functions in extracellular vesicles is the growth differentiation factor 9 (GDF-9), and the mechanism of action thereof for restoring the ovary is determined, and therefore extracellular vesicles (GOEs) that overexpress GDF-9 serve as an active substance, and by means of extraction and purification of said component, the purpose of targeted therapy is achieved.

This invention discloses an AI-based personalized dynamic embryo culture system, belonging to the field of embryo culture technology. The system adopts a modular architecture, including a core control module, at least one independent culture chamber module, an AI analysis module, and a dynamic regulation module. By employing microfluidic chip technology and an integrated microsensor array, this invention achieves high-precision real-time monitoring of embryo morphology images and physiological parameters of the culture medium. Combined with multimodal data fusion analysis using the AI ​​analysis module, it significantly improves the accuracy and reliability of embryo developmental potential assessment, thereby contributing to increased rates of high-quality embryos and clinical pregnancy success. Furthermore, this invention, through a built-in personalized protocol generation unit, can dynamically generate and execute personalized culture protocols based on the patient's age, ovarian function indicators, and basal hormone levels, while utilizing the dynamic regulation module to simulate the uterine diurnal rhythm for temperature fluctuation control.

The invention provides a Chinese herbal medicine leavening agent for improving the egg laying performance of hens in the later egg laying period as well as a preparation method and application of the Chinese herbal medicine leavening agent. The Chinese herbal medicine leavening agent is obtained by fermenting compound Chinese herbal medicines including motherwort, angelica sinensis, ligusticum wallichii, peach kernels, astragalus membranaceus and baked ginger with compound probiotics, namely bacillus subtilis, saccharomyces cerevisiae and lactobacillus plantarum. The compound probiotics are adopted for solid-state fermentation of the compound Chinese herbal medicine, strain compatibility is reasonable, the process is simple and efficient, synergistic fermentation is achieved, and release of active ingredients of the Chinese herbal medicine can be effectively promoted; the Chinese herbal medicine leavening agent is added into hen feed in the later egg laying period in proportion, the fat metabolism of hens can be adjusted, the content of intestinal digestive enzymes and reproductive hormone can be increased, the ovarian function of laying hens can be improved, the egg laying performance and the egg quality can be improved, and the Chinese herbal medicine leavening agent has good application prospects.

The invention belongs to the technical field of biological medicines, and particularly relates to application of an SIRT5 inhibitor MC3482 in preparation of a medicine for treating premature ovarian failure. According to the invention, a mouse POI model is constructed through the induction of cyclophosphamide (CTX), and the MC3482 is proved to be capable of inhibiting the activity of SIRT5, reducing excessive macrophage infiltration of ovary caused by CTX, reducing M1 type macrophage activation and proinflammatory factor release, further inhibiting the apoptosis of ovarian granular cells, protecting follicular reserve and recovering ovarian functions. The invention clarifies the action effect and application scheme of MC3482 for preventing and treating POI, provides a new treatment strategy for chemotherapy-induced iatrogenic POI, and has important clinical transformation value.

This application relates to the field of medical data processing technology and discloses a method and system for screening infertile patients with polycystic ovary syndrome (PCOS). The method includes: acquiring data on the number of antral follicles, anti-Müllerian hormone (AMH) concentration, and ovarian volume from multiple patient monitoring cycles; performing feature extraction and normalization to obtain a set of normalized feature vectors; determining the synchronous relationship between the number of antral follicles and ovarian volume based on the vector set, and identifying signs of asynchronous changes; combining hormone concentrations for joint grouping to obtain the distribution of abnormal indicator clusters and identifying ovarian function stage markers; performing sequence matching based on the stage markers of continuous cycles and historical medical records to generate an ovarian function progression trajectory curve; extracting inflection point features from the curve and performing causal association rule mining to construct a logical chain between abnormal indicators and clinical outcomes; and determining conditions layer by layer according to the logical chain to output the final screening results. This application improves the accuracy of screening infertile patients with PCOS.

The invention discloses a stem cell exosome composition for improving premature ovarian failure as well as a preparation method and application of the stem cell exosome composition. The composition is composed of human umbilical cord mesenchymal stem cell exosomes obtained through hypoxia and TGF-beta1 combined pretreatment and resveratrol, and the human umbilical cord mesenchymal stem cell exosomes and the resveratrol are compounded according to a specific mass ratio. The pre-treatment condition is that 1% oxygen concentration and 10 ng / ml TGF-beta1 are co-cultured for 48 hours, and the condition can synergistically up-regulate the expression level of specific miRNA in the exosome. The composition prepared through physical incubation and an ultrafiltration method shows a clear synergistic treatment effect in vitro and in vivo, the combination index of the composition is 0.38-0.45, ovarian endocrine indexes can be effectively recovered, follicular reserve can be protected, and oxidative stress and inflammation states of ovarian tissues can be remarkably improved. The invention provides a novel treatment strategy with a novel mechanism and a remarkable curative effect for premature ovarian failure, especially chemotherapy-induced ovarian function impairment.

The invention relates to the technical field of biological medicine, in particular to application of an lnc81 related reagent in ovarian function impairment related products. The invention provides an application of an lnc81 related reagent in ovarian function impairment related products, and provides a new biomarker for detecting ovarian function impairment, the biomarker is lnc81, and by using the marker, the false positive risk can be reduced, the detection accuracy is improved, the trauma of tissue biopsy is avoided, and the risk of ovarian function impairment is reduced. The method is suitable for dynamically monitoring curative effect or relapse.

The invention provides a transdermal absorption composition containing six active peptides and application of the transdermal absorption composition. The transdermal absorption composition is prepared from 0.5 to 5 parts of acetyl hexapeptide-8, 0.5 to 5 parts of decapeptide-4, 0.5 to 5 parts of oligopeptide-1, 1 to 10 parts of glycoprotein, 1 to 8 parts of serum protein, 5 to 20 parts of soluble collagen, 3 to 12 parts of mannitol, 2 to 10 parts of trehalose, 1 to 5 parts of caprylyl glycol and 5 to 25 parts of butanediol. The composition is used for preparing transdermal absorption products for improving ovarian functions and delaying ovarian aging. Through a penetration enhancer combination and raw material modification process, the technical problems that polypeptide is difficult to transdermal and easy to inactivate are effectively solved, and the skin permeability and stability of active ingredients are improved, so that the ovarian function is improved through synergistic interaction.

The invention provides a diagnostic application of NDUFS5 in premature ovarian insufficiency disease, the NDUFS5 peripheral blood expression level (mRNA) is detected to have a significant difference between POI and a control group, the difference is verified by qPCR in an independent queue, and the result shows that the expression of the NDUFS5 gene in the premature ovarian insufficiency group is significantly reduced compared with the control group, and the NDUFS5 gene has a significant effect on the premature ovarian insufficiency disease. The trend is consistent with that of transcriptome sequencing, and meanwhile, training and verification data are combined to prove that the NDUFS5 can be applied to distinguishing normal ovarian functions and ovarian insufficiency. The kit can be used for diagnosis of premature ovarian insufficiency (premature ovarian failure and ovarian aging), solves the clinical dilemma that diagnosis is delayed by means of existing means for POI diseases in the prior art, enables high-risk groups to be capable of early prediction or early warning, and avoids the risk that irreversible fertility is lost in advance due to the fact that the optimal period of early intervention is missed.

Compositions and methods for suppressing ovarian function in subjects with hormone receptor-positive breast cancer.

The invention belongs to the technical field of biological medicine manufacturing, and particularly relates to a pharmaceutical preparation for improving ovarian functions and a preparation method thereof. The pharmaceutical preparation comprises the following raw materials in parts by weight: 12-25 parts of berberine hydrochloride, 8-16 parts of shionone, 5-10 parts of dicliptera chinensis polysaccharide, 10-20 parts of a diluent, 5-9 parts of an adhesive and 1-6 parts of a lubricant. According to the pharmaceutical composition, berberine hydrochloride, shionone and dicliptera chinensis polysaccharide are compounded, sexual cycle disorder caused by the polycystic ovarian syndrome is adjusted in a synergistic interaction mode, insulin resistance is improved, indexes such as luteinizing hormone (LH), follicle-stimulating hormone (FSH) and LH / FSH are remarkably improved, and the pharmaceutical composition has the application potential of treating the polycystic ovarian syndrome and has good application prospects. And the market prospect is wide.